MDCG 2020‑16 rev.5 Released! Decoding IVD Classification Rules under IVDR - Wiselink Group-A More Controllable, Stable, and Future-Oriented Material Direction

Home > News Center > MDCG 2020‑16 rev.5 Released! Decoding IVD Classification Rules under IVDR

MDCG 2020‑16 rev.5 Released! Decoding IVD Classification Rules under IVDR

Time：2026-09-11 11:22:22

The Medical Device Coordination Group (MDCG) has published MDCG 2020‑16 rev.5, the core guidance document supporting Regulation (EU) 2017/746 (IVDR) for in‑vitro diagnostic medical devices. While the overall classification framework remains unchanged, it provides further clarifications on the rationale for Rule 7 regarding classification of control materials. This update is critical for Chinese IVD manufacturers undertaking EU CE registration, risk determination and technical documentation compilation.

原

文

链

接

https://health.ec.europa.eu/latest-updates/mdcg-2020-16-rev5-guidance-classification-rules-vitro-diagnostic-medical-devices-under-regulation-eu-2026-09-09_en

一、Fundamental Principle

Under IVDR, IVD products are assigned to four risk classes: Class A (lowest risk) ＜ Class B ＜ Class C ＜ Class D (highest risk).

Primary classification criterion：Risk class is determined exclusively by the intended purpose stated by the manufacturer in labelling, IFU (Instructions for Use) and technical documentation, NOT by technology platform or instrument hardware.

Higher‑risk precedence principle：Where multiple classification rules apply to one device, the highest applicable risk class shall be adopted.

Practical Pitfall：If foreseeable off‑label use for higher‑risk scenarios exists, clear usage limitations must be specified in IFU. Otherwise, regulators may upgrade the risk classification of your device.

Special requirements apply to medical device software, IVD kits, calibrators, controls, near‑patient testing and self‑testing devices, which cannot follow the classification of reagents in a simplistic manner.

二、Plain‑language Interpretation of the Seven Classification Rules

Rule1｜Class D – Highest‑Risk Devices

A device shall be classified as Class D if any of the following criteria are met:

Devices for detecting transmissible agents in donations of blood, blood components, cells, tissues or organs, to assess suitability for transfusion, transplantation or cell administration;
Devices detecting transmissible agents causing life‑threatening diseases with high or suspected high propagation risk, e.g. HBV, HCV, HIV, Ebola, highly virulent influenza, MERS‑CoV;
Devices determining infectious load for life‑threatening infectious diseases, where monitoring is critical for patient management, such as HIV viral load, HBV‑DNA and HCV viral load assays.

Class D devices are subject to stringent compliance requirements, including review input from EU Reference Laboratories, mandatory annual post‑market surveillance and Periodic Safety Update Reports (PSUR).

Rule2｜Blood Grouping & Tissue Typing: Partial Class D, Remaining Class C

Applicable to blood grouping, foeto‑maternal blood group incompatibility testing and tissue typing to ensure immunological compatibility for transfusion or transplantation:

Class D：Assays targeting markers within ABO, Rh, Kell, Kidd and Duffy blood‑group systems (including molecular genotyping and reverse blood grouping);

Class C：Other typing assays such as HLA human leukocyte antigen typing.

Rule3 (a‑m)｜Class C High‑Risk Devices (If not classified as Class D under Rule 1 / Rule 2)

device falls into Class C when satisfying any of the sub‑clauses below, covering most high‑risk clinical IVD scenarios:

a) Devices for detection of sexually‑transmitted agents (HPV, Chlamydia trachomatis, Treponema pallidum, etc.);

b) Detection of infectious agents (excluding antibody assays) in cerebrospinal fluid or blood with moderate propagation risk;

c) Assays for infectious agents where erroneous results may lead to death or severe disability for test subjects, foetuses or their offspring;

d) Prenatal screening to assess women’s immune status against transmissible agents; e) Determination of infectious or immune status, whereby incorrect patient‑management decisions may endanger patients or their offspring;

f) Companion Diagnostics (CDx); g) Disease staging (excluding cancer staging), where false results may trigger life‑threatening outcomes;

h) Screening, diagnosis or staging of cancer (including pre‑malignant lesions)

; i) Human genetic testing: prenatal testing, carrier screening, newborn screening, pharmacogenomics, direct‑to‑consumer (DTC) genetic testing

; j) Monitoring levels of medicinal products or biological components, where erroneous results could cause life‑threatening consequences;

k) Devices for managing patients suffering from life‑threatening diseases or conditions;

l) Screening for congenital disorders in embryos or foetuses (including Non‑Invasive Prenatal Testing, NIPT);

m) New‑born screening for congenital disorders, where missed detection may result in death or severe disability (e.g. phenylketonuria, congenital hypothyroidism).

Common Misconceptions of Companion Diagnostics (CDx)：Not all drug‑related assays qualify as CDx

Not CDx：Therapeutic drug‑level monitoring; dose adjustment for patients already eligible for a medicinal product.

Mandatory CDx criteria：Essential for safe and effective use of a medicinal product with an INN (International Nonproprietary Name); identifies, before or during treatment, patients most likely to benefit OR patients at elevated risk of serious adverse drug reactions. (Refer to the decision‑making flowchart in Annex 2 of the guidance document). For CDx devices, consultation opinions from EMA or national medicines agencies are required in addition to notified‑body assessment.

Rule4｜Self‑Testing & Near‑Patient Testing

4 (a) Self‑testing (tests performed by lay persons): Default Class C

Only the following limited exceptions are classified as Class B: pregnancy tests, fertility tests, cholesterol assays; urine tests for glucose, erythrocytes, leucocytes and bacteria.

Note: If one kit contains both Class B and Class C markers, the whole kit shall take the higher Class C classification. Specimen collection performed by lay persons without conducting analytical test steps does NOT constitute self‑testing.

4 (b) Near‑Patient Testing (POCT): No automatic risk upgrade

Point‑of‑care test classification is purely driven by intended purpose. POCT devices can fall under Class A / B / C / D.

Rule5｜Class A – Lowest‑Risk Devices

a) General laboratory‑use products, accessories without critical characteristics, buffer solutions, washing solutions, general culture media and histological stains, when explicitly intended by the manufacturer for IVD examinations;

b) Instruments specifically built for IVD workflows, such as PCR thermal cyclers and clinical chemistry analysers. Note: Instruments with integrated direct‑measurement sensors shall be re‑classified separately.

c) Specimen receptacles: blood collection tubes, urine cups, saliva collection devices, solely for sample preservation and transport without analytical testing functions.

Most Class‑A devices can follow self‑declaration procedures. Sterile Class‑A devices still require notified‑body involvement.

Rule6｜Class B – Moderate‑Risk Devices

All IVD devices not covered by Rule 1‑5 are classified as Class B. This category covers most hormone assays, vitamin testing, electrolyte panels, routine pathogen antibody assays and conventional influenza tests. Erroneous results are unlikely to cause serious patient harm.

Rule7｜Class B (Key revision in rev.5)

Control materials without manufacturer‑assigned qualitative or quantitative values shall be classified as Class B.

Important distinction: Reference ranges provided by manufacturers do NOT count as assigned values. Calibrators and control materials with assigned values shall adopt the risk class of their corresponding assay reagents.

三、Classification for Combined IVD Products

A frequent compliance mistake: Classifying an entire kit merely based on one single component. This practice is incorrect!

Complete kits: The overall risk class follows the kit’s stated intended purpose, applying the higher‑risk precedence rule.
Independent assessment for individual components: Instruments, reagents, buffers, calibrators and controls shall be evaluated separately.
Calibrators & assigned‑value controls inherit the risk class of matching reagents; unassigned controls follow Rule 7 as Class B.
Software driving an instrument shares the instrument’s risk class. Stand‑alone analytical software shall be classified according to its own intended purpose.
Buffers and wash solutions without critical characteristics generally fall into Class A.

四、Five Common Pitfalls for Chinese IVD Manufacturers Exporting to EU

Ambiguous intended‑purpose claims：Vague statements in IFU are a top reason for notified‑body non‑conformities, which may trigger risk‑class upgrade.

Confusion between POCT and self‑testing：Lay‑person sample collection ≠ self‑testing. Self‑testing applies once end‑users perform hands‑on analytical steps such as sample loading or incubation.

Mis‑identification of Companion Diagnostics (CDx）：Therapeutic drug monitoring and dose‑calculation assays are frequently mis‑categorised as CDx and will fail assessment.

Misclassification of control materials：Distinguish between “reference range” and “manufacturer‑assigned value”; rev.5 further clarifies Rule 7 boundaries.

Neglecting software classification：Report‑generating software and AI‑aided pathology analysis software qualify as IVD software and require dedicated classification assessment.

五、Closing Remarks

MDCG 2020‑16 rev.5 does not restructure the overall classification framework but sharpens the boundaries for control‑material classification. IVD risk classification defines conformity‑assessment pathways, technical‑documentation depth, performance‑evaluation scope and post‑market surveillance obligations.Chinese IVD enterprises are advised to complete classification justification referencing MDCG 2020‑16 at project initiation, and archive full classification rationale within technical documentation, to reduce rectification risks during notified‑body audits.

Previous：Major New Regulations for Hong Kong Aesthetic Medicine! Mandatory Listing for Injectable Products! Next：Australia's TGA Adds New Class IIa Classification Rule! CDSS Exemption Provisions Updated Simultaneously

Fill Form

Whether you need more information or wish to cooperate with us, we will guide you through every step of the regulatory process. Subscribe to our newsletter for the latest global regulatory updates.